Invesco BLDRS Europe Select ADR Index Fund
Most Recent
A Closer Look at Novartis’s Innovative Medicines Segment
Novartis’s Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology.
Novartis ADR’s Performance and Revenue Estimates for Q3 2018
Novartis’s (NVS) stock price has increased ~14.3% in the third quarter, and its stock rose ~2.8% year-to-date on October 2.
Novartis to Divest Portions of Sandoz US to Aurobindo
Novartis (NVS) announced today that it has agreed to sell select portions of its Sandoz US portfolio to Aurobindo Pharma USA.
EC Approves GSK’s Nucala for Children with Severe Asthma
On August 30, GlaxoSmithKline (GSK) announced that the EC approved Nucala for pediatric patients with severe refractory eosinophilic asthma.
Novartis’s Sandoz in Q2 2018
Novartis’s (NVS) Sandoz reported nearly flat revenues at ~$2.46 billion in Q2 2018 compared to $2.45 billion in the second quarter of 2017.
Novartis’s SOLAR-1 Trial Met Primary Endpoint
Novartis (NVS) announced on August 23 that its SOLAR-1 trial evaluating alpelisib combined with fulvestrant has met its primary endpoint.
What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2
GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes its wellness, oral health, nutrition, and skin health products.
Assessing the Performance of Novartis Stock in 1Q18
Novartis stock has fallen ~7.0% in 1Q18, and it’s fallen 4.5% YTD (year-to-date) as of April 6, 2018.
How Novartis’s Alcon Performed in 4Q17
Alcon reported 8% growth in revenues to ~$1.6 billion during 4Q17 as compared to ~$1.4 billion in 4Q16.
How AstraZeneca’s Other Products Portfolio Performed in 4Q17
AstraZeneca’s (AZN) other products portfolio reported revenues of ~$1.1 billion during 4Q17, a 17% decline in operating revenues.
Sanofi’s Generics and Consumer Healthcare Portfolios in 4Q17
Sanofi’s consumer healthcare portfolio reported revenues of 1.2 billion euros in 4Q17, reflecting 51.8% growth in operating revenues compared to 4Q16.
How the Ablynx Acquisition Strengthens Sanofi’s R&D Strategy
Sanofi (SNY) is consistently investing in and focusing on its R&D (research and development) strategy. The company has a number of key technology platforms driving its multitargeting strategy in R&D.
Novartis’s 4Q17 Earnings: Segment-Wise Revenues
Novartis (NVS) reported revenues of ~$12.9 billion in 4Q17, representing 5.0% growth in revenues compared to ~$12.3 billion in 4Q16.
Shingrix Could Be a Long-Term Growth Driver for GlaxoSmithKline
On October 20, 2017, the U.S. Food and Drug Administration (or FDA) approved GlaxoSmithKline’s (GSK) Zoster vaccine recombinant and adjuvanted vaccine, Shingrix.
Why Mizuho Securities Upgraded Teva Pharmaceutical to a ‘Buy’
On January 9, 2018, Mizuho Securities upgraded Teva Pharmaceutical Industries (TEVA) from a “neutral” to a “buy” rating. It came after Teva announced its business restructuring plan.
How Is Novartis’s Lucentis Positioned after 1H17?
In 1H17, Novartis’s (NVS) Lucentis reported revenues of around $922 million, which is a ~1% decline on a year-over-year (or YoY) basis.
How TEVA’s Respiratory Franchise Is Positioned after 1H17
In 1H17, Teva Pharmaceutical’s (TEVA) respiratory franchise reported revenues of ~$626 million, or ~8% lower YoY (year-over-year).
AstraZeneca’s Segment-Wise Performance in 2Q17
At constant exchange rates, AstraZeneca reported an 8% decline in its product sales of ~$4.9 billion during 2Q17.
Performance of Sanofi’s Established Products in 2Q17
Established products Sanofi’s (SNY) established products contributed over 29.5% of its total revenue in 2Q17. Established product revenue, which fell 2.3% at constant exchange rates in 2Q17, stood at 2.6 billion euros. Lower sales of Plavix, Lovenox, Allegra, Myslee, Lasix, and a few other drugs were substantially offset by strong performance by Renagel, Renvela, Aprovel, Synvisc, […]
GlaxoSmithKline’s 2Q17 Earnings: HIV Business
GSK’s HIV Products franchise reported growth of 29.0% to ~1.1 billion pounds in 2Q17 compared to 2Q16.
A Look at Novartis’s Financial Guidance and Priorities for 2017
Novartis expects to absorb the impact of generic competition and expects its 2017 sales to be in line with its 2016 revenue at a constant exchange rate.
